GSK plc (LON:GSK) Declares GBX 15 Dividend

GSK plc (LON:GSKGet Free Report) declared a dividend on Wednesday, May 1st, Upcoming.Co.Uk reports. Stockholders of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share on Thursday, July 11th. This represents a dividend yield of 0.9%. The ex-dividend date is Thursday, May 16th. The official announcement can be accessed at this link.

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,811.72 ($22.75) on Wednesday. The stock has a market capitalization of £73.92 billion, a price-to-earnings ratio of 1,660.55, a price-to-earnings-growth ratio of 1.20 and a beta of 0.27. The business’s fifty day moving average price is GBX 1,676.28 and its two-hundred day moving average price is GBX 1,571.85. GSK has a fifty-two week low of GBX 1,302.60 ($16.36) and a fifty-two week high of GBX 1,821 ($22.87). The company has a debt-to-equity ratio of 134.34, a current ratio of 0.87 and a quick ratio of 0.73.

Analyst Upgrades and Downgrades

A number of research firms have commented on GSK. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.67) price target on shares of GSK in a research report on Tuesday, May 7th. JPMorgan Chase & Co. increased their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the stock an “underweight” rating in a report on Thursday, May 2nd. Berenberg Bank increased their price objective on GSK from GBX 1,650 ($20.72) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a research report on Wednesday, February 14th. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, May 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 ($24.49) target price on shares of GSK in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, GSK presently has a consensus rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.05).

View Our Latest Stock Report on GSK

Insider Buying and Selling

In other GSK news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction on Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.82), for a total value of £2,317,751.36 ($2,911,016.53). In other news, insider Urs Rohner purchased 434 shares of the company’s stock in a transaction dated Wednesday, March 20th. The stock was bought at an average cost of GBX 1,662 ($20.87) per share, for a total transaction of £7,213.08 ($9,059.38). Also, insider Emma Walmsley sold 139,792 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of GBX 1,658 ($20.82), for a total value of £2,317,751.36 ($2,911,016.53). 1.77% of the stock is currently owned by company insiders.

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Dividend History for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.